In vitro sensitization of MK1775 to Ara-C in AML, ALL, and CML cells
| Cell line . | 72 h . | 96 h . | ||
|---|---|---|---|---|
| AraC → MK1775 . | AraC + MK1775 . | AraC → MK1775 . | AraC + MK1775 . | |
| TF-1 | 1.6 | 2.3 | 2.3† | 3.6† |
| THP-1 | 12.0 | 12.0 | 32.0 | 97.0 |
| HEL | 1.3 | 1.8 | 3.1 | 3.9† |
| MDS-L | 4.0 | 5.0 | 1.3† | 4.0* |
| MV4;11 | 12.0 | 12.0 | 7.6† | 11.5* |
| GM03761 | 4.0 | 4.5 | 2.9 | 27.0* |
| K562 | 1.4 | 2.9 | 3.4 | 17.0† |
| Jurkat | 10.0 | 15.0 | 2.8† | 7.4† |
| Cell line . | 72 h . | 96 h . | ||
|---|---|---|---|---|
| AraC → MK1775 . | AraC + MK1775 . | AraC → MK1775 . | AraC + MK1775 . | |
| TF-1 | 1.6 | 2.3 | 2.3† | 3.6† |
| THP-1 | 12.0 | 12.0 | 32.0 | 97.0 |
| HEL | 1.3 | 1.8 | 3.1 | 3.9† |
| MDS-L | 4.0 | 5.0 | 1.3† | 4.0* |
| MV4;11 | 12.0 | 12.0 | 7.6† | 11.5* |
| GM03761 | 4.0 | 4.5 | 2.9 | 27.0* |
| K562 | 1.4 | 2.9 | 3.4 | 17.0† |
| Jurkat | 10.0 | 15.0 | 2.8† | 7.4† |
Summary of Ara-C EC50 shifts of 8 AML, ALL, and CML cell lines treated with Ara-C alone or in combination with MK1775 at 50, 100, and 300nM. The -fold sensitization is shown for Ara-C followed by MK1775 (AraC → MK; sequential dosing) and AraC + MK1775 (AraC + MK; simultaneous dosing) at 72 and 96 hours. Table shows the -fold shifts for 300nM MK1775 except as indicated. See supplemental Figure 5B for corresponding drug-dose–response curves/graphs from simultaneous dosing.
50nM MK1775.
100nM MK1775.